| __timestamp | Grifols, S.A. | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 660772000 | 165772000 |
| Thursday, January 1, 2015 | 736435000 | 196614000 |
| Friday, January 1, 2016 | 775266000 | 303251000 |
| Sunday, January 1, 2017 | 860348000 | 366406000 |
| Monday, January 1, 2018 | 814775000 | 434407000 |
| Tuesday, January 1, 2019 | 942821000 | 468711000 |
| Wednesday, January 1, 2020 | 985616000 | 516922000 |
| Friday, January 1, 2021 | 1061508000 | 739560000 |
| Saturday, January 1, 2022 | 1190423000 | 1002140000 |
| Sunday, January 1, 2023 | 1254234000 | 1161300000 |
| Monday, January 1, 2024 | 1242157000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Grifols, S.A. and Incyte Corporation have demonstrated contrasting approaches to SG&A cost management.
From 2014 to 2023, Grifols, S.A. consistently reported higher SG&A expenses, peaking at approximately 1.25 billion in 2023. This represents a 90% increase from their 2014 figures. In contrast, Incyte Corporation's SG&A expenses grew more modestly, from around 166 million in 2014 to 1.16 billion in 2023, marking a significant 600% increase.
While Grifols, S.A. maintains a steady growth in expenses, Incyte's rapid increase suggests aggressive expansion strategies. Investors and analysts should consider these trends when evaluating the companies' operational efficiencies and long-term strategies.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and Grifols, S.A.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Incyte Corporation
GSK plc or Incyte Corporation: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Incyte Corporation vs Insmed Incorporated
Breaking Down SG&A Expenses: Incyte Corporation vs Walgreens Boots Alliance, Inc.
Cost of Revenue: Key Insights for Incyte Corporation and Grifols, S.A.
Selling, General, and Administrative Costs: Incyte Corporation vs Verona Pharma plc
Incyte Corporation and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Grifols, S.A. vs Ultragenyx Pharmaceutical Inc.
Grifols, S.A. vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Grifols, S.A. vs Travere Therapeutics, Inc. Trends and Insights